Vanguard’s Biggest Bond ETF Becomes First to Break $100 Billion

Gene Therapy for Kids’ Deadly Muscle Disease Fails to Reach Trial Goal 

With Yields Above 5%, Some Investors Say It's Safe to Start Buying Bonds Again

Biggest Treasury ETF Sees Largest Exodus Since 2020 Meltdown

Catalent Is Linked to Regeneron’s Eye-Drug Rejection in Latest Misstep

Catalent Cuts Annual Forecast More Than Expected, Delays Earnings Report Again

Drug Contractor Catalent Plunges After Annual Guidance Cut, Results Delayed